Repeating earlier claims that Cephalon Inc.'s board of directors had not engaged in timely discussions about his company's $5.7 billion, $73-a-share bid for Cephalon, Valeant Pharmaceuticals International Inc. Chairman and CEO J. Michael Pearson said that Valeant would appeal directly to Cephalon shareholders by commencing a consent solicitation process next week to replace Cephalon's board with Valeant's nominees.